Now Hyglos - Profos AG has been acquired by private investors
The new holders of the company are investors coming from science and industry (Hyglos Invest GmbH and bioMérieux S.A.).
The focus of Hyglos GmbH is the production and distribution of products and services developed within the last years on the basis of the patented phage-protein technology.
Several projects have achieved production level and additionally to the established product portfolio with the main segments "EndoLine" and "Food Diagnostics" further product launches are planned.
For customers and business partners little has changed besides of the new company data.
For the future success of the new company the investment structure is advantageous for all parties: Scientific contributions foster new scientific cooperations and industrial partnership will open new market segments and improve customer access. Investment consulting will strengthen the financial situation and finally lead the new company to business success.
About Hyglos Invest GmbH
Hyglos Invest GmbH was founded in 2009 and is the investor company for Hyglos GmbH.
A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety.
bioMérieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Further information can be found at http://www.biomerieux.com/.
About Profos AG
Hyglos GmbH was founded in 2009 as the follow-up company of former Profos AG founded in 2000. Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phageprotein technology for pharmaceutical, diagnostic and research applications. For more information, call Hyglos GmbH at +49-941-942 620 or write to firstname.lastname@example.org.